SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice

Published: 12 November 2021

  • Views:

    Views Icon 5480
  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 5480
  • Likes:

    Heart Icon 7
Part 3

of 3

Treatment Options in CKD

Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink

Overview

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) and Prof Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice.

 

This three-part series, 'SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice', brings together three experts to review the implications for pathophysiology, screening and treatment strategies.

This programme is supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Recall the existing relationship between chronic kidney disease and cardiovascular disease for patients with and without type 2 diabetes.
  • Consider the global burden of CKD, including for patients with type 2 diabetes, and be aware of existing guidelines for screening.
  • Review treatment options for the treatment of patients with chronic kidney disease, and the role of SGLT2i therapies in available strategies.

Target Audience

  • Cardiologists
  • Endocrinologists
  • Renal specialists

More from this programme

Faculty biographies